Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

2.60EUR
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
€2.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
113,675
52-wk High
€4.83
52-wk Low
€2.44

Latest Key Developments (Source: Significant Developments)

3D Signatures Signed Collaboration Agreement With Mdxhealth SA To Evaluate Co's Prognostic Test Candidate For Prostate Cancer
Wednesday, 28 Mar 2018 08:00am EDT 

March 28 (Reuters) - 3D Signatures Inc ::3D SIGNATURES - SIGNED COLLABORATION AGREEMENT WITH MDXHEALTH SA TO EVALUATE CO'S PROGNOSTIC TEST CANDIDATE FOR PROSTATE CANCER.3D SIGNATURES INC - CO, MDXHEALTH WILL SHARE COSTS OF CONDUCTING COLLABORATIVE STUDY.3D SIGNATURES - ALSO GRANTED MDXHEALTH EXCLUSIVE OPTION TO NEGOTIATE A LICENSE AGREEMENT FOR THE PROGNOSTIC TEST CANDIDATE FOR PROSTATE CANCER.  Full Article

MDxHealth Says SelectMDx Liquid Biopsy Test In 2018 European Association Urology Guidelines
Monday, 19 Mar 2018 02:00am EDT 

March 19 (Reuters) - MDXHEALTH SA ::REG-MDXHEALTH (R): SELECTMDX LIQUID BIOPSY TEST FOR PROSTATE CANCER INCLUDED IN THE 2018 EUROPEAN ASSOCIATION UROLOGY GUIDELINES.INCLUSION OF SELECTMDX IN EUROPEAN ASSOCIATION UROLOGY GUIDELINES TO ENABLE ADOPTION OF TEST IN EU MEMBER STATES SPECIFIC GUIDELINES.INCLUSION OF SELECTMDX IN EUROPEAN ASSOCIATION UROLOGY GUIDELINES TO CONTRIBUTE TO DRIVE PAYOR ADOPTION.  Full Article

Mdxhealth FY Total Revenue Up 35 pct at 40 Million Dollars
Thursday, 22 Feb 2018 01:00am EST 

Feb 22 (Reuters) - MDXHEALTH SA ::FY TOTAL REVENUE OF $40 MILLION UP 35% WITH CONTINUED STRONG VOLUME GROWTH.CASH AND CASH EQUIVALENTS OF $16.8 MILLION AS OF DECEMBER 31, 2017.FY EBITDA LOSS OF $10.4 MILLION VERSUS LOSS OF $ 11.1 MILLION YEAR AGO.FY NET LOSS $12.3 MILLION VERSUS LOSS OF $13.2 MILLION YEAR AGO.CLEAR FOCUS FOR MDXHEALTH’S GROWTH IN 2018 AND BEYOND.ON CONFIRMMDX PRODUCT: SAYS DELIVERY OF PROJECTED NUMBER OF BILLABLE CASES FAILED TO MATERIALIZE DUE TO UNFORESEEN OPERATING ISSUES.ON CONFIRMMDX PRODUCT: THEREFORE EXPECTS A PORTION OF THE CASES TO ROLL OVER INTO 2018.  Full Article

MDxHealth teams up with Ferrer for distribution of its prostate cancer test SelectMDx in Spain
Monday, 20 Nov 2017 01:30am EST 

Nov 20 (Reuters) - MDXHEALTH SA : :REG-MDXHEALTH TEAMS UP WITH PHARMACEUTICAL COMPANY FERRER FOR DISTRIBUTION OF ITS PROSTATE CANCER TEST SELECTMDX IN SPAIN.‍UNDER TERMS OF THIS FIVE-YEAR EXCLUSIVE AGREEMENT, A TEAM OF 10 REPS FROM FERRER'S SALES FORCE OF ARE GOING TO SELL SELECTMDX TEST DIRECTLY TO 1000 UROLOGISTS IN SPAIN​.  Full Article

MDxHealth 9M total revenue at 30.5 million dollars
Thursday, 2 Nov 2017 02:00am EDT 

Nov 2 (Reuters) - MDXHEALTH SA :9M (NOT Q3) NET LOSS $‍​7.4 MILLION VERSUS LOSS OF $10.3 MILLION YEAR AGO.CASH AND CASH EQUIVALENTS ON SEPTEMBER 30, 2017 OF $22.9 MILLION.9M TOTAL REVENUE OF $30.5 MLN‍​.9M EBITDA IMPROVED BY 34.1% FROM $-6.2 MILLION COMPARED TO $-9.1 MILLION IN 2016‍​.TARGETS LOWER END OF ITS 55%-75% PRODUCT AND SERVICE REVENUE GROWTH GUIDANCE FOR 2017.2017 TOTAL REVENUE IS EXPECTED TO GROW BY APPROXIMATELY 60%-70%, TO $48-$51 MILLION.EXPECTS TO MAINTAIN A BALANCE OF CASH AND CASH EQUIVALENTS OF APPROXIMATELY $15 MILLION AT THE END OF 2017.  Full Article

MDxhealth enters distribution agreement with Unilabs for SelectMDx
Monday, 30 Oct 2017 02:00am EDT 

Oct 30 (Reuters) - MDXHEALTH SA ::‍MDXHEALTH ENTERS INTO DISTRIBUTION AGREEMENT WITH UNILABS FOR SELECTMDX FOR PROSTATE CANCER.​.  Full Article

MDxHealth appoints Michael K. Brawer as Chief Medical Officer‍​
Wednesday, 6 Sep 2017 01:00am EDT 

Sept 6 (Reuters) - MDXHEALTH SA ::ANNOUNCES APPOINTMENT OF MICHAEL K. BRAWER, MD AS CHIEF MEDICAL OFFICER‍​.  Full Article

MDxHealth H1 EBITDA rises to 1.4 million dollars
Thursday, 31 Aug 2017 01:30am EDT 

Aug 31 (Reuters) - MDXHEALTH SA ::H1 ‍TOTAL REVENUE OF $24.3 MILLION, UP 87% FROM $12.9 MILLION IN 2016​.H1 ‍PRODUCT REVENUE WAS $12 MILLION, UP 10% FROM $10.9 MILLION;​.H1 ‍OPERATING PROFIT OF $0.6 MILLION COMPARED TO AN OPERATING LOSS OF $7.5 MILLION YEAR AGO​.‍FOR 2017 MAINTAINS ITS PRODUCT AND SERVICE REVENUE GUIDANCE OF GROWTH BETWEEN 55% TO 75%, EXCLUDING ROYALTIES AND MILESTONE PAYMENTS​.H1 EBITDA $1.4 MILLION VERSUS LOSS OF $6.7 MILLION YEAR AGO.H1 NET INCOME $538,000 VERSUS LOSS OF $7.6 MILLION YEAR AGO.  Full Article

MDxHealth announces results identifying lack of knowledge on new generation biomarker tests for prostate cancer
Monday, 3 Jul 2017 01:14am EDT 

July 3 (Reuters) - MDXHEALTH SA ::ANNOUNCES RESULTS FROM AN INDEPENDENT SURVEY IDENTIFY LACK OF KNOWLEDGE ON NEW GENERATION BIOMARKER TESTS FOR PROSTATE CANCER.  Full Article

MdxHealth Q1 revenue growth of 128%, or $19.4 million
Monday, 8 May 2017 01:01am EDT 

May 8 (Reuters) - MDXHEALTH SA ::Q1 SHARP REVENUE GROWTH OF 128%, OR $19.4 MILLION, COMPARED TO THE SAME PERIOD IN 2016.CASH AND CASH EQUIVALENTS ON APRIL 30 2017 OF $35.1 MILLION.THE COMPANY MAINTAINS ITS GUIDANCE FOR THE 2017 FISCAL YEAR.FOR 2017: GROWTH BETWEEN 55% TO 75% ON PRODUCT AND SERVICE INCOME.  Full Article

BRIEF-MDxHealth Announces Positive Clinical Updates For ConfirmMDx

* REG-MDXHEALTH ANNOUNCES POSITIVE CLINICAL UPDATES FOR CONFIRMMDX